Clinical Trial Update: Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemcitabine with pazopanib as second-line therapy in metastatic or relapsed uterine leiomyosarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leiomyosarcoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Pazopanib (Pazopanib)

Snippet

Sponsor: UNICANCER | Conditions: Leiomyosarcoma | Phase 2 | Status: COMPLETED